Zheng Quan Zhi Xing·2025-06-11 08:11Core Viewpoint - Qingdao Weilan Biological Co., Ltd. has obtained a new veterinary drug registration certificate for "Prednisolone Tablets," marking a significant advancement in the treatment of canine allergic and inflammatory diseases [1][2]. Group 1: New Veterinary Drug Information - The new veterinary drug, "Prednisolone Tablets," is classified as a Category V new veterinary drug and is approved for treating allergic and inflammatory diseases in dogs, including non-specific eczema, summer dermatitis, and allergic conditions [2][3]. - The drug is developed by a consortium of companies, including Qingdao Weilan Biological Co., Ltd. and its subsidiaries, with a total research and development investment of 1.7444 million yuan [2][3]. Group 2: Market Background - Skin diseases have the highest incidence among pet diseases, particularly in dogs, with recurrent skin conditions accounting for over 75% of total incidence rates [2][3]. - There is a limited variety of drugs available for treating inflammatory skin diseases in pets, primarily relying on glucocorticoids, which have significant side effects and metabolic burdens [3][4]. Group 3: Drug Development and Impact - Prednisolone is a modified glucocorticoid with four times the anti-inflammatory activity of hydrocortisone and reduced sodium retention, making it suitable for animals with liver dysfunction [3][4]. - The approval of the new veterinary drug reflects the company's commitment to technological innovation and is expected to create new growth opportunities for the business [4].